Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc-99m tilmanocept for lymph node mapping in CNS malignancies
NCT04096716Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in central nervous system tumor, sponsored by Washington University School of Medicine. Started Dec 2019; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT04096716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096716.